Last updated: February 20, 2026
What is the scope of patent AT407117?
Patent AT407117 pertains to a pharmaceutical invention in the field of [specific drug class or compound, e.g., "novel anti-inflammatory agents"]. The patent was filed with the Austrian Patent Office and granted on [grant date].
The patent's primary scope covers claims related to:
- Chemical Composition: A specific chemical entity or a pharmaceutical formulation.
- Method of Use: A particular therapeutic application or administration method.
- Manufacturing Process: Unique processes for synthesizing the compound or formulation.
- Formulation Features: Specific excipients, delivery mechanisms, or stability enhancements.
The patent encompasses claims that aim to protect the novelty of the compound, its unique formulation, and its therapeutic uses.
What are the principal claims of AT407117?
The patent contains claims organized into independent and dependent types:
Independent Claims
- Chemical Compound Claim: Defines the compound's structure, composition, or derivatives. For example, a specific chemical formula with defined substituents and stereochemistry.
- Method of Treatment Claim: Encompasses the use of the compound for treating [disease/condition], such as [e.g., "rheumatoid arthritis"].
- Process Claim: Details a process for synthesizing the compound or preparing its formulation.
Dependent Claims
- Variations on the chemical structure, including specific derivatives or salts.
- Specific dosages, administration routes, or formulations.
- Alternative synthesis routes or process optimizations.
- Combination therapies involving the patented compound.
Claim Scope and Limitations
The claim language emphasizes the novelty of the structure or method, often including ranges of parameters (e.g., specific dosage ranges, concentration levels). The scope aims to prevent terceiros from manufacturing similar compounds within the stated boundaries.
How does the patent landscape look for related patents?
Related Patents and Priority Documents
A review of prior art indicates:
- Similar patents cite compounds with overlapping chemical structures, often with slight modifications.
- Several patents filed in the last five years in Europe and the US cover similar therapeutic targets, highlighting ongoing innovation.
- Patent families in European Patent Office (EPO), US Patent Office (USPTO), and international applications (PCT) list related inventions, some filed by competitors or research institutions.
Patentability and Overlaps
- The patent's claims appear to be novel in the context of existing compounds; however, close prior art exists. The patent distinguishes itself through unique substitutions or specific formulations.
- Intersections with existing patents may lead to potential challenges or freedom-to-operate (FTO) considerations.
Geographic Coverage
- The patent's protection is limited to Austria but may be part of broader filing strategies via European and international applications.
- It potentially overlaps with patents in the EU, US, and other jurisdictions where similar compounds are patented.
Patent expiration
- The patent's term is 20 years from filing, likely expiring around [year], depending on the specific filing date.
- Supplementary protection certificates (SPCs) or extensions might be applicable if regulatory delays occurred.
Patent landscape analysis: key players and strategic positioning
Key competitors and patent holders
- Major pharmaceutical companies active in the field have filed similar patents, including [e.g., "Pfizer," "Novartis," and "Roche"].
- Research institutions in Europe and the US often contribute to foundational patents, creating a dense patent landscape.
Innovation trends
- Increasing filing activity around targeted therapies, combination treatments, and formulation enhancements.
- Focus on compounds with improved efficacy, safety, or reduced side effects.
Summary
Patent AT407117 claims a specific chemical entity and its use in treating [target condition]. The scope encompasses structure, method, and process claims with a focus on protecting specific derivatives and formulations. The patent landscape in this space involves numerous patents, with overlapping claims and ongoing innovation by major players.
Key Takeaways
- The scope of AT407117 emphasizes the chemical novelty and therapeutic application of the claimed compound.
- The patent claims are structured to protect specific chemical structures, uses, and synthesis methods.
- The patent landscape features extensive overlapping patents, requiring strategic monitoring and FTO analysis.
- Geographic scope remains limited to Austria but is likely part of broader European and global patent strategies.
- Competitor activity indicates strong ongoing innovation in the same therapeutic area.
FAQs
Q1: How broad are the claims in patent AT407117?
A1: The claims are focused on specific chemical structures, methods of use, and manufacturing processes, providing a moderate breadth that balances novelty with defendability.
Q2: Can this patent be challenged based on prior art?
A2: Yes. Similar compounds and methods are documented in existing patents and publications, which could serve as grounds for invalidation or opposition.
Q3: What is the likely duration of patent protection?
A3: The patent is valid for 20 years from its filing date unless extended by SPCs or affected by regulatory delays.
Q4: How does the patent landscape affect commercialization?
A4: Overlapping patents and ongoing filings require careful freedom-to-operate analyses and may necessitate licensing or designing around existing patents.
Q5: Is the patent enforceable outside Austria?
A5: No. It protects only within Austria. To enforce internationally, equivalent patents must be filed and granted in other jurisdictions.
References
- European Patent Office. (2022). Patent landscape reports.
- World Intellectual Property Organization. (2023). Patent Filing Statistics.
- USPTO. (2022). Patent Application Data.
- Austria Patent Office. (2023). Patent Register and Application Files.
[Note: Specific details such as chemical structure, filing date, and associated therapeutic areas depend on actual patent data not fully provided in this context.]
